Gen9: Ginkgo Bioworks Acquires Gen9

Ginkgo Bioworks said today it has acquired synthetic DNA provider Gen9 for an undisclosed price, in a deal the buyer said will enable it to improve its speed and capacity in constructing new organism designs for use across multiple industries. The acquisition, Ginkgo said, combines will bring into its automated organism engineering foundries Gen9's expertise in assembling pathway-length synthetic DNA. Ginkgo's facilities will house Gen9's BioFab manufacturing platform and proprietary technologies, software, and informatics tools, as well as Gen9's intellectual property portfolio of more than 125 patents and patents pending related to DNA synthesis and assembly technologies. Gen9's operations and research and development teams will also join Ginkgo, bringing with them their expertise in gene synthesis. "Ginkgo has been our largest customer in recent years, and we're thrilled to join forces and together forge a new trajectory for bringing the benefits of synthetic DNA to ...